September 24, 2024 11:45 ET | Source: Transgene S.A. Transgene S.A.
Rapport Semestriel 2024
Pièce jointe
Transgene to Deliver an Oral Presentation on its Individualized Neoantigen Therapeutic Vaccine TG4050 at the World Vaccine Congress
Transgene Continues Progress to Reshape Early-Stage Cancer Treatment through Individualized Neoantigen Therapeutic Vaccines (INTV)
